Colorectal cancer is one of the leading causes of cancer death in North America. Since the treatment of colonic cancer remains difficult due to the lack of effective chemotherapeutic agents, it is important to search for cellular functions that can be disrupted by chemotherapeutic drugs and inhibit the development or progression of this disease. Modification of proteins by myristoylation has been  recognized as important in the function of various viral, oncogenic, and signal-transduction proteins and thus has been proposed as a target for chemotherapeutic drug design. However, the activity  of the enzyme that catalyzes this modification. N-myristoyltransferase has not been investigated in cancer relative to normal tissue. This review mainly focuses on the role of myristoylation in the pathogenesis of colon cancer and highlights the importance of N-myristoyltransferse as a potential marker for the early detection of colon cancer.